|Bid||0.9950 x 0|
|Ask||1.0000 x 0|
|Day's range||1.0000 - 1.0550|
|52-week range||0.9650 - 3.0400|
|Beta (5Y monthly)||0.51|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||2.28|
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) and Neuren Pharmaceuticals Limited (ASX: NEU) announced today that the U.S. Food and Drug Administration (FDA) granted Rare Pediatric Disease (RPD) designation to trofinetide for the treatment of Rett syndrome, a serious and rare neurological disorder. Upon FDA approval of a product with RPD designation, the sponsor may be eligible to receive a Priority Review Voucher, which can be used to obtain FDA review of a New Drug Application for another product in an expedited period of six months.
Unless you borrow money to invest, the potential losses are limited. But when you pick a company that is really...
By buying an index fund, you can roughly match the market return with ease. But if you pick the right individual...
We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are...
Every investor in Neuren Pharmaceuticals Limited (ASX:NEU) should be aware of the most powerful shareholder groups. Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller com...